论文部分内容阅读
目的:观察阿托伐他汀对急性心肌梗死(AMI)患者血清高敏C反应蛋白(hsCRP)、内皮素1(ET1)、心肌肌酸激酶同工酶(CKMB)的影响,探讨阿托伐他汀在斑块稳定性和炎症反应中的作用。方法:选取AMI患者59例,按发病前是否因心绞痛、降脂服用过阿托伐他汀分为治疗组[27例,服阿托伐他汀(20mg,qd)2周以上]与对照组(32例,未服阿托伐他汀)。采用放射免疫法、酶联免疫吸附法检测2组患者血清hsCRP、ET1、CKMB水平。结果:治疗组血浆hsCRP、ET1、CKMB水平低于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀可抑制炎症反应,改善内皮功能,稳定粥样斑块,缩小心肌梗死范围。
Objective: To observe the effect of atorvastatin on serum hs-CRP, ET1 and CKMB in patients with acute myocardial infarction (AMI) and to investigate the effect of atorvastatin on Plaque Stability and Inflammatory Response. Methods: Fifty-nine AMI patients were divided into treatment group (27 cases, atorvastatin 20 mg qd for more than 2 weeks) and control group (32 cases) by angina pectoris or lipid lowering atorvastatin. Cases, not taking atorvastatin). Serum hsCRP, ET1 and CKMB levels were measured by radioimmunoassay and enzyme-linked immunosorbent assay. Results: The plasma levels of hsCRP, ET1 and CKMB in the treatment group were lower than those in the control group (P <0.05). Conclusion: Atorvastatin can inhibit the inflammatory response, improve endothelial function, stabilize atherosclerotic plaque and reduce the range of myocardial infarction.